Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBORAN durvalumab consolidation after chemoradiotherapy in limited-stage small cell lung cancer
2025-521340-37-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoints: Incidence of grade >=3 adverse events, Incidence of immune-mediated adverse events and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-521340-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521340-37-00.